Novartis says EU approves expanded use of Glivec

February 27, 2012

Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive (GIST)," Novartis said in a statement.

"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the ," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

Explore further: NGOs protest Novartis' Glivec patent quest in India

Related Stories

NGOs protest Novartis' Glivec patent quest in India

February 23, 2012

Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.